A setback for arthritis gene therapy

The first death of a patient involved in a trial of gene therapy for rheumatoid arthritis is discussed in a commentary in the current issue of Arthritis Research & Therapy. Prof Chris Evans and colleagues have collated information about the clinical trial – put on hold following the patient’s death and since restarted with a modified protocol – and discuss it in the wider context of arthritis gene therapy.

Commentary
   

Arthritis gene therapy’s first death
Christopher H Evans, Steven C Ghivizzani, Paul D Robbins
Arthritis Research & Therapy 2008, 10:110 (27 May 2008)
[Abstract] [Full text] [PDF]

This commentary has been made free to access immediately on publication. Arthritis Research & Therapy’s
reviews and commentaries normally require a subscription for access. If
you do not currently have a subscription to the journal you can
register for a free 30-day trial.

Arthritis Research & Therapy is an international,
peer-reviewed online and print journal edited by Prof Peter E Lipsky (USA) and Prof
Sir Ravinder N Maini (UK). The major focus of the journal is in mechanisms of, and translational
laboratory and clinical research into localised and systemic
immune-inflammatory and degenerative diseases of the musculoskeletal
system. Phase I, II and III clinical trials are also published. All research articles published in the journal are open access.

View the latest posts on the On Medicine homepage

Comments

By commenting, you’re agreeing to follow our community guidelines.

Your email address will not be published. Required fields are marked *